T. Rowe Price Associates Portfolio holdings
T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
JPMorgan Chase
JPM
|
+$1.6B |
| 2 |
Verizon
VZ
|
+$1.3B |
| 3 |
US Bancorp
USB
|
+$1.26B |
| 4 |
Berkshire Hathaway Class B
BRK.B
|
+$1.26B |
| 5 |
Lam Research
LRCX
|
+$1.18B |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Amazon
AMZN
|
+$6.33B |
| 2 |
Tesla
TSLA
|
+$5.64B |
| 3 |
Alphabet (Google) Class C
GOOG
|
+$4.91B |
| 4 |
TMX
Terminix Global Holdings, Inc.
TMX
|
+$3.44B |
| 5 |
Meta Platforms (Facebook)
META
|
+$1.4B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 26.7% |
| 2 | Healthcare | 19.64% |
| 3 | Financials | 12.71% |
| 4 | Consumer Discretionary | 10.95% |
| 5 | Communication Services | 7.77% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
2651
Cardlytics
CDLX
$25.4M
| $129K | ﹤0.01% |
2,238
-37
| -2% | -$2.29K |
|
2652
Cogent Biosciences
COGT
$6.55B
| $129K | ﹤0.01% |
11,122
+1,018
| +10% | +$12.6K |
|
|
NKLA
2653
DELISTED
Nikola Corporation Common Stock
NKLA
| $129K | ﹤0.01% |
1,985
+404
| +26% | +$33.8K |
|
|
TWKS
2654
DELISTED
Thoughtworks Holding, Inc. Common Stock
TWKS
| $129K | ﹤0.01% |
12,645
+848
| +7% | +$7.87K |
|
|
GRTS
2655
DELISTED
Gritstone bio, Inc. Common Stock
GRTS
| $129K | ﹤0.01% |
37,300
| – | – |
|
2656
Organogenesis Holdings
ORGO
$232M
| $128K | ﹤0.01% |
47,475
+15,602
| +49% | +$45.5K |
|
2657
Telos
TLS
$338M
| $128K | ﹤0.01% |
25,214
+7,684
| +44% | +$50.9K |
|
2658
NN Inc
NNBR
$298M
| $127K | ﹤0.01% |
84,920
+17,600
| +26% | +$32.6K |
|
2659
ARKO Corp
ARKO
$496M
| $126K | ﹤0.01% |
14,595
+1,364
| +10% | +$12.6K |
|
|
TAST
2660
DELISTED
Carrols Restaurant Group, Inc.
TAST
| $126K | ﹤0.01% |
92,390
-18,500
| -17% | -$28.8K |
|
|
BFX
2661
DELISTED
BowFlex Inc.
BFX
| $126K | ﹤0.01% |
82,600
| – | – |
|
|
EFC
2662
Ellington Financial
EFC
$1.77B
| $125K | ﹤0.01% |
+10,080
| New | +$131K |
|
2663
eHealth
EHTH
$40M
| $124K | ﹤0.01% |
25,580
+676
| +3% | +$2.52K |
|
2664
MiMedx Group
MDXG
$614M
| $124K | ﹤0.01% |
44,763
+12,722
| +40% | +$38K |
|
2665
Repay Holdings
RPAY
$309M
| $124K | ﹤0.01% |
15,348
+1,803
| +13% | +$13K |
|
2666
ADMA Biologics
ADMA
$2.11B
| $123K | ﹤0.01% |
31,829
+2,986
| +10% | +$9.21K |
|
|
CHMI
2667
Cherry Hill Mortgage Investment Corp
CHMI
$108M
| $123K | ﹤0.01% |
21,176
+1,200
| +6% | +$6.74K |
|
2668
Rush Street Interactive
RSI
$2.88B
| $123K | ﹤0.01% |
34,395
+615
| +2% | +$2.28K |
|
2669
Heron Therapeutics
HRTX
$62M
| $121K | ﹤0.01% |
48,237
+2,118
| +5% | +$6.82K |
|
2670
Natural Gas Services Group
NGS
$477M
| $121K | ﹤0.01% |
10,588
-3,300
| -24% | -$36K |
|
2671
Kodak
KODK
$986M
| $120K | ﹤0.01% |
39,277
+828
| +2% | +$3.64K |
|
2672
ClearPoint Neuro
CLPT
$466M
| $119K | ﹤0.01% |
+14,000
| New | +$133K |
|
|
MPX
2673
DELISTED
Marine Products Corp
MPX
| $118K | ﹤0.01% |
+10,022
| New | +$105K |
|
2674
Ocular Therapeutix
OCUL
$2.23B
| $118K | ﹤0.01% |
41,861
+10,972
| +36% | +$36.3K |
|
2675
GoodRx Holdings
GDRX
$1.24B
| $117K | ﹤0.01% |
25,100
| – | – |
|
Similar funds
T. Rowe Price Associates's Q4 2022 Portfolio in Review
As of Q4 2022, T. Rowe Price Associates held 3,066 positions worth $622B, up 1.8% from $610B the previous quarter. Its ten largest holdings account for 27% of the portfolio.
T. Rowe Price Associates's Q4 2022 filing shows 113 new, 1,569 increased, 1,081 reduced and 107 closed positions. Its largest new stake was GE HealthCare: 6,360,001 shares worth $371M. The largest sale was Amazon, an estimated $6.33B.
By sector, the portfolio is most concentrated in Technology at 27% of assets, up from 26% a quarter earlier, followed by Healthcare and Financials.
- T. Rowe Price Associates's largest Q4 2022 buy was GE HealthCare: 6,360,001 shares worth $371M.
- T. Rowe Price Associates added most to JPMorgan Chase in Q4 2022, an estimated $1.6B increase.
- T. Rowe Price Associates's biggest Q4 2022 reduction was Amazon, cutting an estimated $6.33B.
- T. Rowe Price Associates fully exited Terminix Global Holdings, Inc. in Q4 2022, selling an estimated $3.44B.
- T. Rowe Price Associates's ten largest holdings make up 27% of its $622B portfolio in Q4 2022.
- T. Rowe Price Associates opened 113 new positions and closed 107 in Q4 2022.
- T. Rowe Price Associates's portfolio value rose 1.8% quarter-over-quarter to $622B.
Based on T. Rowe Price Associates's 13F filing for Q4 2022, filed 14 Feb 2023.